---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-109035"
form_type: "8-K"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:23:13.537687+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Q2 net loss narrows to $1.9M; revenue drops 99%; going concern warning

## Summary
- Q2 2025 net loss improved to $1.9M from $15.3M in Q2 2024; revenue fell to $6.6K from $618.9K.
- Wugen license suspended for one year; company seeks new partner for HCW9206.
- Raised $5.0M equity in May 2025; extinguished $6.9M debt via restructuring.
- Company expresses substantial doubt about ability to continue as going concern for next 12 months.
- On track to initiate Phase 1 trial for HCW9302 in autoimmune disorder in Q3 2025.

## SEC filing metadata
- accession: 0000950170-25-109035
- form_type: 8-K
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025109035/0000950170-25-109035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025109035/hcwb-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-109035
- JSON: https://secwatch.observer/filing/0000950170-25-109035.json
- Plain text: https://secwatch.observer/filing/0000950170-25-109035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.